Alosetron

Alosetron
Klinički podaci
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	1,5 h
Izlučivanje	Renalno
Identifikatori
CAS broj	122852-42-0
ATC kod	A03AE01 (WHO)
PubChem	CID 2099
IUPHAR/BPS	2296
DrugBank	DB00969
ChemSpider	2015
ChEBI	CHEBI:253342
ChEMBL	CHEMBL1110
Hemijski podaci
Formula	C17H18N4O
Molarna masa	294,351
	SMILES CN1C2=C(C3=CC=CC=C13)C(=O)N(CC1=C(C)NC=N1)CC2; ;
	InChI InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19) ; Key:JSWZEAMFRNKZNL-UHFFFAOYSA-N ;

Alosetron je organsko jedinjenje, koje sadrži 17 atoma ugljenika i ima molekulsku masu od 294,351 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	2
Broj donora vodonika	1
Broj rotacionih veza	2
Particioni koeficijent^[8] (ALogP)	1,7
Rastvorljivost^[9] (logS, log(mol/L))	-3,7
Polarna površina^[10] (PSA, Å²)	53,9

Reference

^ Andresen, V.; Hollerbach, S. (2004). „Reassessing the benefits and risks of alosetron: What is its place in the treatment of irritable bowel syndrome?”. Drug Saf. 27 (5): 283—92. PMID 15061683. doi:10.2165/00002018-200427050-00001. }-
^ Camilleri, M. (2000 Jan). „Pharmacology and clinical experience with alosetron”. Expert Opin Investig Drugs. 9 (1): 147—59. PMID 11060667. doi:10.1517/13543784.9.1.147. Проверите вредност парамет(а)ра за датум: |date= (помоћ)}-
^ Mayer, E. A.; Bradesi, S. (2003 Nov). „Alosetron and irritable bowel syndrome”. Expert Opin Pharmacother. 4 (11): 2089—98. PMID 14596662. doi:10.1517/14656566.4.11.2089. Проверите вредност парамет(а)ра за датум: |date= (помоћ)}-
^ Rahimi R, Nikfar S, Abdollahi M (2008 May). „Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials”. Clin Ther. 30 (5): 884—901. PMID 18555935. doi:10.1016/j.clinthera.2008.05.002. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Lewis JH (2010 Feb). „Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective”. Expert Rev Gastroenterol Hepatol. 4 (1): 13—29. PMID 20136586. doi:10.1586/egh.09.72. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Alosetron

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Andresen, V.; Hollerbach, S. (2004). „Reassessing the benefits and risks of alosetron: What is its place in the treatment of irritable bowel syndrome?”. Drug Saf. 27 (5): 283—92. PMID 15061683. doi:10.2165/00002018-200427050-00001. }-

[2] Camilleri, M. (2000 Jan). „Pharmacology and clinical experience with alosetron”. Expert Opin Investig Drugs. 9 (1): 147—59. PMID 11060667. doi:10.1517/13543784.9.1.147. Проверите вредност парамет(а)ра за датум: |date= (помоћ)}-

[3] Mayer, E. A.; Bradesi, S. (2003 Nov). „Alosetron and irritable bowel syndrome”. Expert Opin Pharmacother. 4 (11): 2089—98. PMID 14596662. doi:10.1517/14656566.4.11.2089. Проверите вредност парамет(а)ра за датум: |date= (помоћ)}-

[4] Rahimi R, Nikfar S, Abdollahi M (2008 May). „Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials”. Clin Ther. 30 (5): 884—901. PMID 18555935. doi:10.1016/j.clinthera.2008.05.002. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[5] Lewis JH (2010 Feb). „Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective”. Expert Rev Gastroenterol Hepatol. 4 (1): 13—29. PMID 20136586. doi:10.1586/egh.09.72. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[6] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[7] Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[8] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[9] Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[10] Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]